“We continued to make progress toward our goal of developing a long-term sustainable genomics business that will impact the diagnosis and treatment of cancer,” said Panna Sharma, CGI’s president and chief executive officer.
RUTHERFORD, N.J., Aug. 8, 2014 (GLOBE NEWSWIRE) — Cancer Genetics, Inc. (Nasdaq:CGIX), an emerging leader in DNA-based cancer diagnostics, announced today that it will report second quarter 2014 financial results on Thursday, August 14, 2014. The Company will issue a press release before the market opens and will host a conference call at 8:30am Eastern […]
CGI’s Proprietary Genomic Panel for Diagnosis and Risk Stratification of Chronic Lymphocytic Leukemia (CLL) and Small Lymphocytic Lymphoma (SLL) is Now Licensed to Report Out Risk Stratification of Patients Into Three Distinct Groups
CGI announces acquisition of Gentris Corp., based in Raleigh, NC. The acquisition adds contracts with five of the top global biopharma companies, and increases CGI’s overall biopharma contract backlog to over $18 Million. Additionally, the acquisition uniquely positions CGI to provide genomic testing globally and expands the company’s footprint to China, one of fastest growing markets for both clinical trials and cancer testing.